calculated and the therapeutic regimen applied. The authors do not state how the papers were assessed for validity, or how many of the reviewers performed the validity assessment.
Data extraction
The authors do not state how many of the reviewers were involved in the process of data extraction. The following data were presented in tables: report type, publication year, whether consecutive patients were enrolled, nationality, disorder, reference standard, check-up time, how treatments were allocated, blinding, antibiotic susceptibility measured, multicentre study, medication combination, loss to follow-up mentioned. For each study the proportion of patients successfully cured using per protocol and intention to treat analyses were calculated.
Methods of synthesis
How were the studies combined? To correct for outlying values and to stabilise the variance in cure rate, arcsin transformation was performed. Cure rates were pooled using a weighted regression analysis, in which all the clinical features and methodological aspects were included simultaneously and this was used to model the heterogeneity in the model. Studies were weighted proportionally to four times the size of the study population. This allowed for the correction of heterogeneity between studies caused by the different study sizes. A random intercept for the study was included to model dependency between outcomes within the same study (it appears that each treatment arm was included separately in the regression analysis and this was included to incorporate the controlled elements for comparison of outcomes that came from the same trial). For each regression model an overall F-test (NDF, DDF) was used to examine whether the hypothesis of no fixed effect should be rejected. NDF is the degree of freedom in the numerator and DDF the degree of freedom n the denominator in the F-test. Each model was corrected for features and methodological aspects that had a substantial bearing on the difference in cure rates between studies. Dose-response and dose-duration relationships were estimated for each drug separately. If the dosage of the drug/treatment was not significant the lowest dose was described.
How were differences between studies investigated?
Heterogeneity was assessed by means of an ordinary least square regression equation in which all the clinical features and methodological aspects were included simultaneously.
Results of the review
A total of 666 manuscripts were included. These related to 1295 trials of 132 different medication combinations.
The average number of patients treated per trial was small, median = 30 (inter-quartile range (IQR): 19-50). The overall cure rate was 71% (IQR: 44-85) in the per protocol analysis and 67% (IQR:42-82) in the intention-to-treat analysis. Variation in eradication rates in the per protocol analysis was related to nationality (F(48;513)=2.04, p<0.01), therapeutic regimen (F(171;513)=21.85, p<0.01) and whether the studies mentioned loss to follow-up (F(1;513), p<0.01). The same variables were associated with variation in eradication rates in the intention-to-treat analysis.
Adjusted cure rates showed that no therapeutic regimen was optimal. The most frequently investigated therapeutic regimen that provided sufficient effectiveness were triple therapies (n=296): two anti-microbial drugs supplemented with a proton-pump inhibitor. A combination of the proton-pump inhibitor plus macrolide plus nitroimidazole (n=122 and 80) cured 87.1% and 82.9% of the patients per protocol and intention to treat respectively. No differences between the proton-pump inhibitors (lansoprazole, omeprazole and panteprozole) or the type of nitroimidazole (metronidazole or tinidazole) used was found. Of the 2 macrolides evaluated, clarithromycin was superior to azithromycin. The dose of clarithromycin influenced the cure rate; 1.5 g of clarithromycin cured H.pylori in more patients than 500mg, 600mg, 750mg or 1g. The dosage of the other drugs did not influence the cure rate. The same antibiotics in combination with ranitidine bismuth subcitrate also performed very well (n=26 and 24),90.8% and 78.4% of patients were cured per protocol and on intention-to-treat bases, respectively. Overall cure rates of between 80 and 85% were achieved using combinations of a proton-pump inhibitor or ranitidine bismuth citrate with 2 antibiotics including clarithromycin, amoxycillin and metronidazole or tinidazole. Comparable cure rates were also achieved using a combination of a protonpump inhibitor of H2-receptor antagonist with bismuth subcitrate or tripotassium dicitrato bismuthate, metronidazole and tetracycline. The duration of any of the treatments did not influence the cure rate of any of the treatment regimens. 
